📗 Cite This Artifact
Cellular Senescence Therapeutic Targeting
Cellular Senescence Therapeutic Targeting
year: 2019
pmid: '30659283'
demaria2014:
authors: Demaria M, et al
title: An essential role for senescent cells in optimal wound healing
journal: Dev Cell
year: 2014
pmid: '25481258'
baker2018:
authors: Baker DJ, Petersen RC
title: Cellular senescence in brain aging and neurodegenerative diseases
journal: Lancet Neurol
year: 2018
pmid: '29371448'
copp2008:
authors: Coppé JP, et al
title: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions
journal: PLoS Biol
year: 2008
pmid: '19177017'
blagosklonny2013:
authors: Blagosklonny MV
title: Rapamycin treatment of human cells
journal: Cell Cycle
year: 2013
pmid: '24217340'
herranz2015:
authors: Herranz N, et al
title: mTOR regulates MAPKAP-K2 activity to regulate the cellular senescence-associated secretory phenotype
journal: Nat Cell Biol
year: 2015
pmid: '26051178'
justice2024:
authors: Justice JN, Nambiar AM, Tchkonia T, et al
title: 'Senolytics: pharmacological interventions for aging'
journal: J Gerontol A Biol Sci Med Sci
year: 2024
hickson2023:
authors: Hickson LJ, Langhi Prata LGP, Bobart SA, et al
title: 'Senolytics decrease senescent cells in humans: a pilot study'
journal: Aging Cell
year: 2023
chaib2022:
authors: Chaib S, Tchkonia T, Kirkland JL
title: 'Cellular senescence and senolytics: the path to translating age-related interventions'
journal: Nat Rev Drug Discov
year: 2022
Cellular Senescence Therapeutic Targeting
year: 2019
pmid: '30659283'
demaria2014:
authors: Demaria M, et al
title: An essential role for senescent cells in optimal wound healing
journal: Dev Cell
year: 2014
pmid: '25481258'
baker2018:
authors: Baker DJ, Petersen RC
title: Cellular senescence in brain aging and neurodegenerative diseases
journal: Lancet Neurol
year: 2018
pmid: '29371448'
copp2008:
authors: Coppé JP, et al
title: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions
journal: PLoS Biol
year: 2008
pmid: '19177017'
blagosklonny2013:
authors: Blagosklonny MV
title: Rapamycin treatment of human cells
journal: Cell Cycle
year: 2013
pmid: '24217340'
herranz2015:
authors: Herranz N, et al
title: mTOR regulates MAPKAP-K2 activity to regulate the cellular senescence-associated secretory phenotype
journal: Nat Cell Biol
year: 2015
pmid: '26051178'
justice2024:
authors: Justice JN, Nambiar AM, Tchkonia T, et al
title: 'Senolytics: pharmacological interventions for aging'
journal: J Gerontol A Biol Sci Med Sci
year: 2024
hickson2023:
authors: Hickson LJ, Langhi Prata LGP, Bobart SA, et al
title: 'Senolytics decrease senescent cells in humans: a pilot study'
journal: Aging Cell
year: 2023
chaib2022:
authors: Chaib S, Tchkonia T, Kirkland JL
title: 'Cellular senescence and senolytics: the path to translating age-related interventions'
journal: Nat Rev Drug Discov
year: 2022
Cellular Senescence Therapeutic Targeting
Path: `/mechanisms/senescence-therapeutic-targeting`
Overview
Cellular senescence represents a fundamental aging mechanism that contributes to neurodegeneration through both cell-intrinsic dysfunction and the senescence-associated secretory phenotype (SASP)[@kirkland2018]. As senescent cells accumulate in the aging brain, they create a chronic pro-inflammatory microenvironment that drives pathology in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders[@baker2018]. Therapeutic targeting of senescence offers two complementary strategies: senolytic drugs that eliminate senescent cells, and senomorphic agents that suppress the harmful SASP without cell death[@he2017].
This page provides a comprehensive overview of therapeutic approaches to target cellular senescence in neurodegenerative diseases, including mechanistic details, clinical trial status, and intervention points for drug development.
Senolytic Drug Mechanisms
Senolytic drugs selectively induce apoptosis in senescent cells while sparing normal cells. The selective toxicity derives from the heightened dependence of senescent cells on anti-apoptotic pathways—particularly the Bcl-2 family proteins—to survive their pro-inflammatory state[@xu2018].
Dasatinib plus Quercetin (D+Q)
The combination of dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) represents the most extensively studied senolytic regimen[@kirkland2018]. This combination was identified through high-throughput screening and demonstrated broad senolytic activity across multiple tissue types[@zhu2016].
Dasatinib is an FDA-approved drug for chronic myeloid leukemia that inhibits multiple kinases including Bcr-Abl and Src family kinases. In senescent cells, dasatinib targets Bcl-2, Bcl-xL, and Bcl-w survival proteins, shifting the balance toward [apoptosis](/entities/apoptosis)[@xu2018].
Quercetin is a natural flavonoid with multiple senolytic mechanisms including PI3K/Akt inhibition, Bcl-2 family modulation, and direct effects on multiple pro-survival pathways[@chaib2022]. The combination achieves synergistic senolytic activity with lower doses of each compound than would be required alone.
The D+Q combination has demonstrated preclinical efficacy in neurodegenerative disease models. In tauopathy mice, senolytic treatment reduced senescent glial cells and prevented tau-dependent pathology progression[@bussian2018]. In Alzheimer's disease models, D+Q reduced cognitive decline and neuroinflammation through clearance of senescent microglia[@musi2018].
Navitoclax (ABT-263)
Navitoclax is a Bcl-2 family inhibitor that targets Bcl-2, Bcl-xL, and Bcl-w[@zhu2016]. Originally developed as an anti-cancer agent, navitoclax demonstrated potent senolytic activity particularly against senescent fibroblasts and [astrocytes](/cell-types/astrocytes).
The mechanism involves:
Navitoclax has shown particular efficacy against senescent [microglia](/cell-types/microglia-neuroinflammation) and neurons in vitro, making it relevant for neurodegenerative applications[@trias2019].
Other Senolytic Candidates
| Agent | Primary Target | Status | CNS Penetration |
|-------|---------------|--------|-----------------|
| ABT-737 | Bcl-2, Bcl-xL, Bcl-w | Preclinical | Limited |
| Fisetin | Multiple | Preclinical | Moderate |
| Piperlongumine | ROS pathways | Preclinical | Unknown |
| 17-DMAG | Hsp90 | Preclinical | Limited |
Senomorphic Approaches (SASP Suppression)
Senomorphic drugs do not eliminate senescent cells but instead suppress the production and secretion of SASP factors[@he2017]. This approach may offer advantages when complete senescent cell removal could have unintended consequences, such as impairing wound healing or tissue repair[@demaria2014].
Rapamycin and mTOR Inhibition
The mechanistic target of rapamycin (mTOR) pathway serves as a central regulator of SASP production[@laberge2015]. Rapamycin inhibits mTORC1, which:
- Reduces NF-κB activity through the kinase complex ILK[@herranz2015]
- Decreases translation of SASP mRNAs via 4E-BP1 phosphorylation
- Suppresses NLRP3 inflammasome activation and IL-1β production[@wang2019]
Rapamycin maintains the senescent cell growth arrest while rendering cells metabolically "quiet" with reduced SASP secretion[@blagosklonny2013]. This dual action—SASP suppression plus [autophagy](/entities/autophagy) induction—makes rapamycin particularly potent.
Metformin
Metformin, the widely prescribed type 2 diabetes medication, exhibits senostatic properties through AMPK activation and subsequent mTOR inhibition[@moiseeva2013]. Metformin:
- Activates AMPK, which inhibits mTOR and reduces SASP
- Alters cellular metabolism to reduce pro-inflammatory signaling
- Modulates mitochondrial function in senescent cells
Large observational studies suggest reduced dementia risk in diabetic patients treated with metformin, and clinical trials are evaluating metformin's neuroprotective effects in non-diabetic patients.
JAK-STAT Inhibition
The JAK-STAT pathway plays a critical role in SASP maintenance and autocrine signaling[@xu2015]. JAK inhibitors including ruxolitinib and tofacitinib:
- Block cytokine signaling required for SASP maintenance
- Reduce production of pro-inflammatory interleukins (IL-6, IL-8)
- Attenuate interferon-responsive gene expression
In preclinical models, JAK inhibition reduced SASP-induced cognitive decline and neuroinflammation.
SASP Modulation Strategies
Beyond direct senolytic and senomorphic approaches, additional strategies target specific aspects of SASP biology:
NF-κB Pathway Inhibition
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) serves as the master regulator of SASP transcription. Inhibitors targeting this pathway include:
- BAY 11-7082: Direct IKK inhibitor
- Pyrrolidine dithiocarbamate: NF-κB DNA binding inhibitor
- Parthenolide: IKK and NF-κB targeting
p38 MAPK Inhibition
p38 mitogen-activated protein kinase contributes to SASP regulation through transcription factor C/EBPβ phosphorylation and SASP mRNA stabilization:
- SB203580: Selective p38α inhibitor
- SB239063: Brain-penetrant p38 inhibitor
IL-1β and NLRP3 Targeting
The NLRP3 inflammasome represents a key SASP-related target:
- MCC950: Potent NLRP3 inhibitor
- Canakinumab: Anti-IL-1β antibody (tested in Alzheimer's disease)
Clinical Trial Landscape
Active Senolytic Trials in Neurodegeneration
| Trial ID | Agent | Phase | Condition | Status |
|----------|-------|-------|-----------|--------|
| NCT02848131 | D+Q | I | COPD/aging | Completed |
| NCT03415087 | D+Q | I | Alzheimer's | Completed |
| NCT04685590 | D+Q | I/II | Parkinson's | Recruiting |
| NCT04833517 | D+Q | II | Cognitive decline | Planning |
Completed Trials and Findings
The first human senolytic trial (NCT02848131) in idiopathic pulmonary fibrosis demonstrated reduced senescent cell burden in peripheral blood with D+Q treatment[@hickson2023]. A Phase I trial in Alzheimer's disease (NCT03415087) established safety and showed biomarker signals consistent with reduced senescence burden.
Challenges and Opportunities
Key challenges for clinical translation include:
Biomarkers for Senescent Cell Burden
Circulating SASP Factors
The senescence-associated secretory phenotype (SASP) includes numerous secreted factors that can serve as biomarkers[@copp2008]:
| Biomarker | Source | Utility |
|-----------|--------|---------|
| IL-6 | Serum | Highest correlation with senescence |
| IL-8 | Serum | SASP marker |
| PAI-1 | Plasma | Senescence-specific |
| CXCL1 | Serum | Pro-inflammatory |
| VEGF | Plasma | Angiogenic SASP |
Senescence Detection Methods
SA-β-Gal staining: Classic histochemical marker; limited to tissue samples
p16 and p21 markers:
- p16INK4a: Cell cycle inhibitor, increasingly used
- p21: Cyclin-dependent kinase inhibitor
- γH2AX foci: DNA damage response
- 53BP1: DNA repair foci
- Single-cell RNA sequencing
- Senescence-associated secretory phenotype profiling
- Machine learning on blood profiles
Disease-Specific Considerations
Alzheimer's Disease
Cellular senescence in AD primarily affects[@ogrodnik2021]:
- Microglia: Senescent microglia accumulate with age and in AD brains, showing increased SASP and reduced phagocytic capacity
- Astrocytes: Senescent astrocytes produce pro-inflammatory cytokines that drive neuroinflammation
- Neurons: Some evidence of neuronal senescence in AD, though controversial
Parkinson's Disease
Senescence in PD involves:
- Dopaminergic neurons: Show markers of senescence in substantia nigra
- Microglia: Chronic senescence in PD brain
- Astrocytes: Contribute to neuroinflammation through SASP
ALS
In ALS, senescence affects:
- Motor neurons: Show evidence of senescence
- Glia: Senescent astrocytes and microglia contribute to toxicity
- Muscle: Early senescence in muscle tissue
Frontotemporal Dementia
FTD shows senescence in:
- Neurons: TDP-43 pathology linked to senescence
- Glia: Region-specific patterns
Emerging Therapeutic Targets
Senolytic Pipeline
| Drug/Compound | Target | Stage | Notes |
|---------------|-------|-------|-------|
| Dasatinib + Quercetin | Bcl-2, PI3K | Phase 1-2 | Most advanced |
| Navitoclax (ABT-263) | Bcl-2/xL/w | Preclinical | Thrombocytopenia |
| Fisetin | Multiple | Preclinical | Natural product |
| ABT-737 | Bcl-2/xL/w | Preclinical | Limited solubility |
| Piperlongumine | ROS pathways | Preclinical | Unclear mechanism |
| 17-DMAG | Hsp90 | Preclinical | Limited CNS penetration |
Senomorphic Pipeline
| Drug/Compound | Target | Stage | Notes |
|---------------|-------|-------|-------|
| Rapamycin | mTOR | Approved (other) | Neuroprotective |
| Metformin | AMPK/mTOR | Approved (DM) | Safety established |
| Ruxolitinib | JAK1/2 | Approved (RA) | Immunosuppression |
| MCC950 | NLRP3 | Preclinical | Potent inflammasome inhibitor |
Novel Approaches
Senolytic antibodies: Targeting senescent cell surface antigens (uPAR, CD9) for antibody-dependent cellular cytotoxicity
Galactoside-based prodrugs: Activated specifically in senescent cells by elevated β-galactosidase
Gene therapy: Targeted expression of pro-apoptotic genes in senescent cells
Combination Strategies
Senolytic-Senomorphic Combinations
Combining senolytic and senostatic approaches may provide synergistic benefits[@kirkland2018]:
- D+Q + Rapamycin: Senolytic clearance plus SASP suppression
- Navitoclax + JAK inhibitors: Dual targeting of senescent cell survival and SASP
- Fisetin + Metformin: Natural senolytic with senostatic effects
Multi-Target Approaches
Targeting multiple hallmarks of aging:
- Senescence + proteostasis (rapamycin)
- Senescence + mitochondrial dysfunction (CoQ10)
- Senescence + neuroinflammation (MCC950)
Safety Considerations
Potential Risks
Off-target effects: Senolytic drugs may affect non-senescent cells, particularly during repeated dosing
Wound healing impairment: Senescent cells play important roles in tissue repair[@demaria2014]
Immune modulation: Chronic senolytic treatment may affect immune surveillance
Thrombocytopenia: Bcl-2 family inhibitors can cause platelet depletion
Monitoring Strategies
- Baseline and serial SASP biomarker measurement
- Platelet counts during Bcl-2 inhibitor treatment
- Cognitive and functional assessments
- Neuroimaging for brain penetration markers
Future Directions
Research Priorities
Emerging Areas
- Senescence vaccines: Active immunization against senescent cells
- Synthetic lethality: Exploiting senescent cell vulnerabilities
- Epigenetic therapies: Modulating senescence gene expression
Related Pages
Related Pages
- [Senolytic Therapies for Neurodegenerative Diseases](/therapeutics/senolytic-therapies-neurodegeneration)
- [Senostatic Therapies for Neurodegeneration](/mechanisms/senostatic-therapies-neurodegeneration)
- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)
- [SASP in Neurodegeneration](/mechanisms/sasp-senescence-associated-secretory-phenotype)
- [Geroprotective Therapies for Neurodegeneration](/mechanisms/geroprotective-therapies-neurodegeneration)
Biomarkers for Senolytic Response
Clinical Biomarkers
Monbut invasive |
SASP as Treatment Response Marker
The senescence-associated secretory phenotype provides accessible biomarkers:
- IL-6: Highest correlation with senescent cell burden
- PAI-1: Plasminogen activator inhibitor-1, highly specific
- CXCL1: Pro-inflammatory chemokine
- VEGF: Angiogenic factor, elevated in senescence
Emerging Biomarkers
Single-cell approaches reveal cell-type-specific senescence signatures:
- snRNA-seq: Identifies senescent cell populations in brain tissue
- proteomics: Maps SASP protein composition
- epigenetic clocks: Biological aging indicators
Regulatory Considerations
FDA Pathway
Senolytics face unique regulatory challenges:
Current Regulatory Status
| Agent | Status | Indication |
|-------|--------|------------|
| Dasatinib | FDA-approved | CML (leukemia) |
| Quercetin | Available as supplement | N/A (not approved) |
| Rapamycin | FDA-approved | Transplant, rare diseases |
| Metformin | FDA-approved | Type 2 diabetes |
Repurposing existing drugs for senolytic indications offers faster development paths.
Research Priorities
Preclinical
Clinical
Future Directions
Novel Modalities
- Senolytic antibodies: Targeted clearance via surface antigens
- Gene therapy: Inducible apoptosis in senescent cells
- Vaccination: Active immunization against senescent cells
- Nanoparticles: Targeted drug delivery
Combination Approaches
Future therapies will likely combine:
Precision Medicine
Understanding cell-type-specific senescenalth and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28593998/)
Pathway Diagram
The following diagram shows the key molecular relationships involving Cellular Senescence Therapeutic Targeting discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-senescence-therapeutic-targeting |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-cd0a2fa8cf23 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-senescence-therapeutic-targeting'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-senescence-therapeutic-targeting?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Cellular Senescence Therapeutic Targeting](http://scidex.ai/artifact/wiki-mechanisms-senescence-therapeutic-targeting)
http://scidex.ai/artifact/wiki-mechanisms-senescence-therapeutic-targeting